These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12784272)

  • 21. Sarizotan as a treatment for dyskinesias in Parkinson's disease: a double-blind placebo-controlled trial.
    Goetz CG; Damier P; Hicking C; Laska E; Müller T; Olanow CW; Rascol O; Russ H
    Mov Disord; 2007 Jan; 22(2):179-86. PubMed ID: 17094088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Minimal clinically important change on the unified Parkinson's disease rating scale.
    Schrag A; Sampaio C; Counsell N; Poewe W
    Mov Disord; 2006 Aug; 21(8):1200-7. PubMed ID: 16673410
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bilateral impairments of skilled reach-to-eat in early Parkinson's disease patients presenting with unilateral or asymmetrical symptoms.
    Doan JB; Melvin KG; Whishaw IQ; Suchowersky O
    Behav Brain Res; 2008 Dec; 194(2):207-13. PubMed ID: 18692094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic treatment of advanced Parkinson's disease: a meta-analysis of COMT inhibitors and MAO-B inhibitors.
    Talati R; Reinhart K; Baker W; White CM; Coleman CI
    Parkinsonism Relat Disord; 2009 Aug; 15(7):500-5. PubMed ID: 19167259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements.
    Mallol R; Barrós-Loscertales A; López M; Belloch V; Parcet MA; Avila C
    Brain Res; 2007 May; 1147():265-71. PubMed ID: 17368575
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subthalamic nucleus stimulation modulates motor cortex oscillatory activity in Parkinson's disease.
    Devos D; Labyt E; Derambure P; Bourriez JL; Cassim F; Reyns N; Blond S; Guieu JD; Destée A; Defebvre L
    Brain; 2004 Feb; 127(Pt 2):408-19. PubMed ID: 14691060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep brain stimulation of the subthalamic nucleus in Parkinson's disease.
    Kawakami N; Jessen H; Bordini B; Gallagher C; Klootwyk J; Garell CP
    WMJ; 2005 Aug; 104(6):35-8. PubMed ID: 16218314
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sweating in Parkinsonian patients with wearing-off.
    Pursiainen V; Haapaniemi TH; Korpelainen JT; Sotaniemi KA; Myllylä VV
    Mov Disord; 2007 Apr; 22(6):828-32. PubMed ID: 17357129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson's disease.
    Cakit BD; Saracoglu M; Genc H; Erdem HR; Inan L
    Clin Rehabil; 2007 Aug; 21(8):698-705. PubMed ID: 17846069
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pain intensity on and off levodopa in patients with Parkinson's disease.
    Nebe A; Ebersbach G
    Mov Disord; 2009 Jun; 24(8):1233-7. PubMed ID: 19412949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
    Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
    Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Six weeks of intensive treadmill training improves gait and quality of life in patients with Parkinson's disease: a pilot study.
    Herman T; Giladi N; Gruendlinger L; Hausdorff JM
    Arch Phys Med Rehabil; 2007 Sep; 88(9):1154-8. PubMed ID: 17826461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Depressive symptoms and motor condition in Parkinson's disease patients].
    Stella F; Bucken-Gobbi LT; Gobbi S; Sant'Ana-Simões C
    Rev Neurol; 2007 Nov 16-30; 45(10):594-8. PubMed ID: 18008264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levodopa effect upon functional balance of Parkinson's disease patients.
    Nova IC; Perracini MR; Ferraz HB
    Parkinsonism Relat Disord; 2004 Oct; 10(7):411-5. PubMed ID: 15465397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
    Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
    Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.